Remeditex Ventures, set up in part by technology transfer professionals at Texas University's UT Southwestern Medical Center, is joined by Amgen's corporate venturing unit backing the round.

Remeditex Ventures, a US-based venture capital (VC) firm set up by former executives at Hunt Petroleum and technology transfer professionals at Texas University’s UT Southwestern Medical Center, led a $20m round for MiRagen Therapeutics, a US-based biopharmaceutical firm to treat muscle disease.

Remeditex was joined in its series B round by Amgen Ventures, the corporate venturing division of biotechnology corporation Amgen and venture peers Atlas Venture, Boulder Ventures and Broadview Ventures.

Miragen picked up an initial $4m of funding for its 2009 series B round, which also included charitable foundation Peierls Foundation.

William Marshall, executive president of MiRagen, said: "This funding strengthens our ability to advance novel microRNA-based therapeutics [master regulators of gene expression] that may address areas of high unmet medical need and improve the lives of patients."

The round followed an $8m series A round the year before in which VCs Atlas Venture and Boulder Ventures were…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?